Abstract:Dennis K Ledford, 1 Warner W Carr, 2 Wendy C Moore, 3 Njira L Lugogo, 4 Arjun Mohan, 4 Bradley Chipps, 5 Alexander R Mackie, 6 Andrew W Lindsley, 7 Joseph Spahn, 6 Christopher S Ambrose 8 1 Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 2 Allergy & Asthma Associates of Southern California, Mission Viejo, CA, USA; 3 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; 4 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA; 5 Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA; 6 BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 7 US Medical Affairs, Amgen, Thousand Oaks, CA, USA; 8 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA Correspondence: Christopher S Ambrose, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA, Tel +1 301-398-4454, Email Purpose: Younger age of asthma onset (AAO) has been associated with an allergic phenotype, whereas eosinophilic phenotypes have been associated with older AAO. In randomized trials, biologic efficacy among adults with severe asthma (SA) has varied by age at asthma onset. To determine whether these associations observed in trials apply to real-world outcomes, this study examined biologic effectiveness by AAO and biologic class in a large, real-world cohort. Patients and methods: CHRONICLE is an ongoing, real-world study of US adults with subspecialist-treated SA receiving biologics, maintenance corticosteroids, or who are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled between February 2018 and February 2022 who initiated a biologic for SA and had complete data for analysis were included. A locally estimated scatterplot smoothing (LOESS) analysis was used to plot the relationship between percentage exacerbation rate reduction and AAO by biologic class. Results: Of 578 patients with complete data, 198, 149, and 231 were diagnosed with asthma at age < 18, 18– 39, and ≥ 40 years, respectively. Across subgroups, patients were predominantly White (72– 78%), female (67– 73%), and commercially insured (54– 71%). In the LOESS analysis, exacerbation rate reductions were similar for anti-IgE and anti–IL-5/5R and anti–IL-4R subgroups with younger AAO, but the exacerbation rate reduction diminished for patients with older AAO receiving anti-IgE therapy, particularly with asthma onset age ≥ 40 years. Conclusion: Clinicians should consider age of onset in biologic treatment decisions, given reduced effectiveness of omalizumab in patients with asthma onset at age ≥ 40 years. Clinicaltrials.gov Identifier: NCT03373045. Keywords: Biologics, severe asthma, anti-interleukin therapy, anti-immunoglobulin E therapy, effectiveness, age of asthma onset Severe asthma (SA) affects 5%–10% of patients with asthma and is heterogeneous. In multiple studies, childhood-onset asthma has been associated with allergic inflammation, whereas adult-onset asthma has been associated with eosinophilic inflammation. 1–5 In randomized, placebo-controlled trials (RCTs) of biologics for SA treatment, exacerbation reduction magnitude varied by age of asthma onset (AAO). Anti-immunoglobulin E (IgE) therapy (approved for allergic asthma) demonstrated a trend of reduced efficacy with AAO >40 years, 6 whereas biologics approved for eosinophilic asthma (anti–interleukin [IL]-5/5 receptor [R] and anti–IL-4R) demonstrated reduced efficacy with AAO <18 years ( Supplemental Table 1 ). 7–10 However, these differences among RCT subgroups are small and could be due to unidentified variables, limited sample size, or chance. To determine whether these efficacy trends are present in real-world outcomes, we examined exacerbation rate reductions with biologic initiation by AAO and biologic class in a large, real-world study cohort of adults with specialist-treated SA. CHRONICLE is an ongoing, real-world, observational study of US adults with subspecialist-treated SA who are receiving biologics approved by the US Food and Drug Administration for SA, systemic corticosteroids or other systemic immunosuppressants for ≥50% of the prior 12 months, or are persistently uncontrolled (per European Respiratory Society and American Thoracic Society guidelines) while treated with high-dosage ICS with additional controllers. 11 Included patients are aged ≥18 years at enrollment, treated by pulmonologists or allergist-immunologists, and diagnosed with SA ≥12 months before enrollment; written i -Abstract Truncated-

Cognitive Impairment In Severe Asthma - Long-Term Effects Of Biologicals

Effect of long-term inhaled corticosteroids therapy on cognitive function in patients with bronchial asthma and chronic obstructive pulmonary disease

Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

Effectiveness and safety of biological therapy in patients with severe asthma in a real clinical practice

Suboptimal response to biologics in severe asthma patients with humoral immunodeficiencies

Effects of biologics in obese severe asthmatic patients

Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study

Is asthma associated with cognitive impairments? A meta-analytic review

Long-term safety, durability of response, cessation and switching of biologics

Response to Biologic Therapy in Patients with Asthma and Reduced Pulmonary Diffusion Capacity

Late Breaking Abstract - The impact of biologic therapy on work capacity and workforce withdrawal in severe asthma

Relapsing Eosinophilia in a Severe Allergic Asthma Patient on Biological Therapy

Biologics in severe eosinophilic asthma treatment: four years of a single-centre follow-up

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center

A Focus on Small Airways

Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

Bronchiectasis in severe asthma: clinical and inflammatory response to biologic therapy.

How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit

Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study

The Impact of Biological Therapies and the Significance of Their Adherence on Asthma Outcomes